OTTMUSG00000017827 Inhibitors
The proposed inhibitors for LOC628053 are selected based on their known impacts on cellular pathways and processes that could intersect with the potential functions of an uncharacterized protein. Brefeldin A, Cycloheximide, and MG-132 target fundamental aspects of protein synthesis, transport, and degradation, potentially impacting the overall cellular environment in which LOC628053 functions. Rapamycin, Staurosporine, LY294002, U0126, SB203580, Wortmannin, and PD98059 act on key signaling pathways like mTOR, PI3K/AKT, and MAPK/ERK, which are crucial for various cellular processes. The inhibition of these pathways might indirectly affect the activity or stability of LOC628053.
Dasatinib and Imatinib, as broad-spectrum kinase inhibitors, target a range of kinases, potentially impacting signaling pathways or protein interactions relevant to LOC628053. The use of these inhibitors could provide insights into the functional networks and pathways associated with LOC628053, despite the protein's uncharacterized nature. It's important to note that these inhibitors are not confirmed to directly inhibit LOC628053. They represent a starting point for further research to understand the role and regulation of LOC628053 in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting the exchange of guanine nucleotide on ARF proteins, potentially impacting cellular processes involving LOC628053. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide, a protein synthesis inhibitor, can potentially inhibit the synthesis of LOC628053 by blocking translational elongation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that could indirectly affect LOC628053 by altering protein degradation pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and proliferation, which could indirectly affect the pathways involving LOC628053. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a broad-spectrum kinase inhibitor, could indirectly affect LOC628053 by inhibiting various kinases. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that could indirectly influence the function of LOC628053 by modulating the PI3K/AKT signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2 in the MAPK/ERK pathway, potentially affecting processes or pathways in which LOC628053 is involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which could indirectly influence the cellular functions involving LOC628053. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that could indirectly affect LOC628053 through its influence on the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK in the MAPK/ERK pathway, potentially impacting the function of LOC628053. | ||||||